Lanoxin (Digoxin) Can Increase Ejection Fraction in Heart Failure Patients
Based on FDA labeling and clinical evidence, Lanoxin (digoxin) increases left ventricular ejection fraction in patients with congestive heart failure, while ivabradine does not directly increase ejection fraction—it primarily reduces heart rate and hospitalizations. 1
Direct Evidence for Ejection Fraction Improvement
Lanoxin (Digoxin)
The FDA-approved prescribing information for Lanoxin explicitly states that it "increases left ventricular ejection fraction" in adults with mild to moderate heart failure 1. This is supported by clinical research demonstrating that oral digoxin improves left ventricular ejection fraction in elderly patients with congestive heart failure in sinus rhythm, with mean ejection fraction increasing from 0.36 to 0.45 (p < 0.01) 2.
The 2008 ESC Guidelines confirm that digoxin treatment "improves ventricular function" in patients with heart failure due to left ventricular systolic dysfunction 3. However, it's critical to note that while digoxin increases ejection fraction and reduces hospitalizations, it has no effect on mortality 1.
Ivabradine
Ivabradine works through a fundamentally different mechanism—it selectively inhibits the If current in the sinoatrial node, providing pure heart rate reduction without direct inotropic effects 4, 5, 4.
The primary benefit of ivabradine is reduction in heart failure hospitalizations, not ejection fraction improvement. The 2022 AHA/ACC/HFSA Guidelines (Class IIa recommendation) indicate ivabradine "can be beneficial to reduce HF hospitalizations and cardiovascular death" in symptomatic HFrEF patients with LVEF ≤35%, sinus rhythm, and heart rate ≥70 bpm despite maximally tolerated beta-blocker therapy 5, 6.
While some meta-analyses suggest ivabradine may modestly improve LVEF (mean difference 3.89%, 95% CI 2.61-5.17) 7, and one small study showed improvements when added to carvedilol 8, these effects are secondary to heart rate reduction and reverse remodeling, not direct positive inotropy like digoxin provides.
Clinical Context and Positioning
Digoxin is specifically indicated when you need to improve contractility and ejection fraction in patients with:
- Mild to moderate heart failure with systolic dysfunction
- Inadequate response to ACE inhibitors and diuretics 9
- Sinus rhythm or atrial fibrillation requiring rate control 3
Ivabradine is indicated when you need heart rate optimization in patients with:
- Symptomatic HFrEF (LVEF ≤35%)
- Sinus rhythm with resting heart rate ≥70 bpm
- Already on maximally tolerated beta-blocker (only 25% of SHIFT trial patients were on optimal beta-blocker doses) 4, 5, 4
Important Caveats
For digoxin:
- Therapeutic window is narrow (0.6-1.2 ng/mL recommended, lower than historically used) 3
- Monitor electrolytes closely—hypokalemia increases arrhythmia risk 3
- Some elderly patients achieve maximal ejection fraction improvement at serum levels <1.0 ng/mL 2
- Dose adjustments required for renal impairment and elderly patients 1
For ivabradine:
- Must optimize beta-blocker therapy first given proven mortality benefits 4, 5, 4
- Common side effects include bradycardia, atrial fibrillation, and visual disturbances (phosphenes) 7, 10
- Only 17% of well-managed HFrEF patients on optimal guideline-directed medical therapy actually meet criteria for ivabradine 11
Bottom Line
If your goal is to increase ejection fraction, choose Lanoxin (digoxin)—it has direct positive inotropic effects and FDA-approved labeling for this indication. If your goal is to reduce heart rate and hospitalizations in a patient already on maximal beta-blocker therapy, choose ivabradine. These drugs serve different therapeutic purposes in the heart failure treatment algorithm.